Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Engineered Urethral Constructs for Urethral Strictures
NCT03258658Phase 1Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2027
- Primary completion
- Jun 2029
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous engineered urethral construct in urethral stricture, sponsored by Wake Forest University Health Sciences. Primary endpoint: Adverse Events at 36 months. Planned start Jan 2027; status: recruiting.
02
Drugs
autologous engineered urethral construct
03
Conditions
urethral stricture
Beyond the preview
Go deeper on NCT03258658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258658.